ULTRAGENYX PHARMACEUTICAL INC. Defined Contribution Plan, Cost
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Defined Contribution Plan, Cost of $10.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. defined contribution plan, cost for the quarter ending 2015-12-31 was $200.00K.
- ULTRAGENYX PHARMACEUTICAL INC. defined contribution plan, cost for the quarter ending 2015-09-30 was $200.00K.
- ULTRAGENYX PHARMACEUTICAL INC. defined contribution plan, cost for the quarter ending 2015-06-30 was $149.00K.
- ULTRAGENYX PHARMACEUTICAL INC. defined contribution plan, cost for fiscal 2025 was $10.00M, a 0.00% change from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. defined contribution plan, cost for fiscal 2024 was $10.00M, a 0.00% change from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. defined contribution plan, cost for fiscal 2023 was $10.00M, a 11.11% increase from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. defined contribution plan, cost for fiscal 2022 was $9.00M, a 63.64% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $10.00M 10-K · filed 2026-02-18 | ||||
| 2024-12-31 | $10.00M 10-K · filed 2026-02-18 | $9.80M 10-K · filed 2025-02-19 | |||
| 2023-12-31 | $10.00M 10-K · filed 2026-02-18 | $9.70M 10-K · filed 2024-02-21 | |||
| 2022-12-31 | $9.00M 10-K · filed 2025-02-19 | ||||
| 2021-12-31 | $5.50M 10-K · filed 2024-02-21 | ||||
| 2020-12-31 | $4.30M 10-K · filed 2023-02-17 | ||||
| 2019-12-31 | $3.60M 10-K · filed 2022-02-15 | ||||
| 2018-12-31 | $2.90M 10-K · filed 2021-02-12 | ||||
| 2017-12-31 | $2.10M 10-K · filed 2020-02-14 | ||||
| 2016-12-31 | $1.50M 10-K · filed 2019-02-20 | ||||
| 2015-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $400.00K derived: sum of 2 quarters · filed 2018-02-21 | $549.00K derived: sum of 3 quarters · filed 2018-02-21 | $600.00K 10-K · filed 2018-02-21 | |
| 2015-09-30 | $200.00K 10-Q · filed 2015-11-10 | $349.00K derived: sum of 2 quarters · filed 2015-11-10 | $400.00K 10-Q · filed 2015-11-10 | ||
| 2015-06-30 | $149.00K 10-Q · filed 2015-08-14 | $272.00K 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |